Purpose. Group B streptococcus (GBS) is an important cause of neonatal sepsis worldwide. Data on the prevalence of maternal GBS colonization, risk factors for carriage, antibiotic susceptibility and circulating serotypes are necessary to tailor adequate locally relevant public health policies.
INTRODUCTION
Group B streptococcus (GBS) is an important cause of neonatal sepsis worldwide and is associated with high mortality in low-and middle-income countries [1] [2] [3] . Maternal vagino-rectal GBS colonization can lead to vertical transmission in utero or during childbirth, causing lifethreatening neonatal infections [4] . To prevent vertical transmission of GBS, intrapartum antibiotics are recommended for women identified as GBS carriers through active screening conducted during the last trimester of pregnancy [5] . The incidence of early-onset GBS sepsis has decreased notably as a result of this measure, but such a strategy is not effective against late-onset sepsis [6] . In certain countries, such as Morocco, GBS is not routinely screened for in all pregnant women and intrapartum antibiotic prophylaxis is restricted to the recognition of determined risk factors, such as maternal fever, prolonged labour or prolonged rupture of membranes. For any of these strategies to work effectively, functional health systems and laboratory facilities are needed, and these are seldom available in the busy maternity units of many middle-and lowincome countries.
An additional strategy to prevent early and late neonatal GBS disease is based on the concept of the 'vertical vaccination' of pregnant women, under the assumption that the antibodies generated after vaccination will be passively transferred to the newborn. Various GBS conjugate vaccines against some GBS capsular polysaccharides are currently being developed [7] . These polysaccharides have chemical and antigenic differences that define 10 GBS capsular types (serotypes) and play a role as virulence factors that are involved in different mechanisms for evading the host immune system. As an example, serotype III, and specifically its particular hypervirulent clone ST17, has been associated with a substantial proportion of invasive cases in infants [8, 9] .
In this paper, we aimed to investigate (a) the prevalence of GBS colonization in pregnant women, (b) the risk factors for GBS carriage, (c) the antibiotic susceptibility of GBS isolates and (d) the circulating serotypes in Morocco. In spite of the paucity of GBS data from Morocco, this pathogen is believed to cause a significant amount of morbidity and mortality in this country. However, preventive strategies are often nonexistent.
METHODS
Study setting and recruitment A prospective study was conducted from March to July 2013 in two different Moroccan hospitals: (1) the Maternit e des Orangers, a public maternal tertiary level hospital in Rabat (Morocco), and (2) the neonatal unit of the Hôpital d'Enfants de Rabat (HER), the reference paediatric hospital for the country.
During the study, the study staff asked pregnant women at gestational ages of between 35 and 37 weeks who attended the general or high-risk antenatal consultations (ANC) whether they would be willing to participate in the study. 'High-risk pregnancy' was defined in this study as any given risk for the mother or foetus that had been identified by the obstetrician in charge. These included pre-existing chronic conditions or diseases of the mother, a previous unfavourable obstetric history, or other maternal, foetal or placental factors identified as potential risks to the outcome of the pregnancy. As some pregnant women may have failed to attend ANC during those weeks, an additional group of women (irrespective of gestational age upon arrival) were enrolled directly at the time of delivery if they arrived in labour without either rupture of membranes or visible haemorrhage. For all groups, women who were 18 years old and above and had provided written informed consent, and women younger than 18 years old for whom a legal guardian had provided permission, and who did not have any known allergy to the materials used to obtain samples, underwent standardized procedures. Due to the limited capacity of the laboratory, only the first three pregnant women who met the inclusion criteria were recruited at each site every day.
Demographic, socio-economic and clinical data were collected via standardized questionnaires. One vagino-rectal and one vaginal swab were collected into Stuart transport medium according to standard methodologies [5] , together with a urine sample and a vaginal smear.
Follow-up
Pregnant women recruited at the ANC were encouraged to attend the hospital for delivery. A unique identification number and a study card were given to them to facilitate the laboratory's feedback at the time of delivery. Pregnant women identified as GBS carriers were treated following the CDC guidelines [5] . The outcome of their delivery and the basic clinical characteristics of their newborns were recorded using standardized forms. Newborn body surface (NBS) samples (ear and pharyngeal) were additionally collected in Stuart transport media within the first 6 h of life. Newborns who showed any sign of infection were transferred and admitted to the neonatology unit of the HER. All children were offered a follow-up paediatric consultation after the tenth day of life. Mothers who did not bring their children to these consultations were contacted by telephone during the first month after the birth of their child. Mothers were also encouraged to take their babies to the HER and identify themselves as study participants if the infants had any symptoms in the first 28 days of life. All infants born of participating pregnant women with a suspected neonatal invasive infection were registered and their clinical data were collected. Blood samples for basic sepsis screening (including 1 ml for blood culture), NBS (if they were younger than 6 h) and cerebrospinal fluid were collected whenever indicated and possible. Clinical management of such patients was performed according to national recommendations.
In addition, and with the objective of obtaining a complementary picture of the aetiology of neonatal sepsis in the same study area during the recruitment period, the first three newborns (irrespective of whether their mothers were part of the study) admitted every day with suspected invasive infection according to the admitting neonatologist (if maternal or a guardian's written consent was obtained) were also recruited at HER's neonatology department with the same procedures.
Laboratory methods
Samples were initially analysed in the medical research laboratory of the Centre Hospitalier Universitaire Ibn Sina (CHIS). Vagino-rectal swabs were spread onto Granada agar that was specific for GBS isolation. The isolates were identified based on colony appearance, Gram stain and standard biochemical tests, using BD Phoenix (Becton-Dickinson, USA) whenever necessary. Blood from newborns was cultured using the BACTEC 9050 (Becton-Dickinson, USA) culture system. The minimal inhibitory concentrations (MICs) (mg/l) for erythromycin, clindamycin, azythromycin, ampicillin, penicillin G, ceftriaxone, ciprofloxacin, meropenem and vancomycin were determined by E-test (BioM erieux, France) according to CSLI guidelines [10] . Streptococcus pneumoniae ATCC 49619 was used as a control strain for disk diffusion antibiotic sensitivity testing. The evaluation of potential vaginosis was conducted using Nugent's score [11] . GBS isolates were molecularly characterized at Hospital Clínic, in Barcelona, Spain. Capsular typing of GBS isolates was performed by multiplex PCR [12, 13] .
Data management and statistical analysis
All study questionnaires were manually verified for completeness, with errors being edited where necessary, and subsequently double entered using a program written in Filemaker Pro 12 (Filemaker inc., Santa Clara, CA, USA). The statistical analyses were performed with Stata 14.1 (Stata Corp., College Station, TX, USA). The study variables were counted and summarized in frequency tables. The data were analysed using the Fisher exact and Chi-square tests. Multivariate analyses were conducted using logistic regression methods. A probability of <0.05 was considered statistically significant.
RESULTS
During the study, a total of 350 pregnant women and 139 neonates born of these women were recruited ( Fig. 1) . Many of the recruited mothers delivered outside of the hospital where they had conducted their antenatal follow-up. Additionally, 160 different newborns with suspected clinical sepsis were also investigated. For the principal maternal analysis, 349 vagino-rectal and vaginal swabs, and 347 vaginal smears and urine samples were available. In addition, 136 ear and pharyngeal cultures from the infants born of these pregnant women were available. The risk factors significantly associated with a vagino-rectal colonization with GBS in a univariate analysis are shown in Table 1 . Pregnant women with a history of hypertension during the current pregnancy had a significantly higher risk of being GBS-colonized [odds ratio (OR) 17 No association was found between the Nugent score and vaginal pruritus (P=0.873) or GBS colonization ( Table 1) . The observed association between vaginal pruritus and GBS colonization remained statistically significant in the group with a normal Nugent's score (P=0.004), but not in the groups with intermediate results or overt vaginosis (P=0.745 and P=0.533, respectively).
Pregnant women's outcomes
Among the 82 GBS strains isolated from pregnant women, 67 (82 %) were available for molecular characterization. Serotypes V, II and III were the most frequently isolated, representing 36 % (24/67), 25 % (17/67) and 18 % (12/67) of the cases, respectively. The remaining detected serotypes included Ia (6/67, 9 %), IV (5/67, 7 %) and IX (3/67, 5 %) ( Table 2 ).
Only 6/67 (9 %) of the strains were erythromycin-resistant (MIC >256 mg l À1 ), while 4/67 (6 %) were clindamycinresistant (MIC >256 mg l
À1
). All strains were fully (100 %) susceptible to penicillin.
When specifically looking at the two more frequent serotypes (II and V), strains belonging to serotype II appeared to be susceptible to all the antimicrobial agents routinely administered as part of antenatal prophylaxis. In contrast, strains belonging to serotype V were more resistant to antimicrobial agents [13 % (3/24) resistant to clindamycin and erythromycin].
Outcomes from newborns born of recruited pregnant women A total of 139 newborns of the recruited 350 pregnant women (40 %) were born in the study maternity wards and in 136 (97 %) NBS swabs were performed ( Table 3 ). The recruited babies were born vaginally in 76 % (106/139) of cases, through vaginally instrumented delivery in 13 % of cases (18/139) and by Caesarean section in 9 % (13/139) of cases. For two of the newborns, no information on the mode of delivery was available. No differences in the newborns' weight, length, or Apgar score at birth were observed in relation to GBS colonization (data not shown). Ten out of 136 children (7.4 %) had at least 1 NBS culture that was positive for GBS, and 8 of these (80 %), where available, were shown to be positive via molecular analysis (Tables 2 and 3) . Two colonized newborns were born of pregnant women with a vagino-rectal culture that was negative for GBS. Colonization of the pregnant women with GBS was significantly associated with newborn superficial colonization (P<0.001).
A borderline association was observed between colonization of the pregnant woman by Escherichia coli and GBS-positive cultures in the newborn (P=0.055). Two of the three mothers colonized by E. coli who had a child with GBS colonization were also colonized by GBS. The borderline association between maternal E. coli colonization and GBS colonization in the newborn must be interpreted with caution due to the low numbers and the confounding effect of simultaneous maternal GBS colonization. All of the strains were fully susceptible to penicillin, erythromycin and clindamycin.
The most common serotypes presented in pregnant women (II and V) were similarly present in infants (Table 2) . However, serotype IV was isolated significantly more frequently in children than among pregnant women (P=0.035), perhaps suggesting an association with transmission (Table 2) . Other comparisons of serotype distribution among the pregnant women group vs newborns with positive blood culture and this group of newborns vs all newborns with any positive peripheral culture were performed, but no significant differences were observed (Table 4) . None of the children born of pregnant women recruited at delivery developed clinical sepsis in the first 48 h, irrespective of NBS results. Only 37 children born of the 82 colonized pregnant women were born in the study maternity wards, and 16 of them (43 %) were followed up during their first month of life, with only 1 being admitted with clinical sepsis (no micro-organisms were isolated in samples obtained as part of the sepsis work-up, and evolution was good).
Neonatal outcomes in recruited sick newborns with suspected sepsis Of the 160 additional recruited newborns with sepsis suspicion in HER, 120 (75 %) were less than 24 h old, and overall 154 (96 %) were less than 7 days old.
Among 160 newborns admitted with clinical sepsis, 158 had blood culture results available, and 31 (19 %) had cerebrospinal fluid samples for meningitis investigation. Among the 158 blood cultures, 15 samples (9 %) were positive. The bacteria isolated in blood included GBS (five cases, 3.2 %; one case was also positive in CSF), Staphylococcus aureus (six cases, 3.8 %), E. coli (one case, 0.6 %), K. pneumoniae (one case, 0.6 %) and Enterococcus (two cases, 1.3 %). One of these GBS-infected newborns died, yielding a case fatality rate of 20 % for GBS infection. Among the 78 infants with available peripheral cultures, 6 (8 %) infants presented at least 1 peripheral culture with GBS growth. All of the GBS detected in those infants were penicillin-susceptible. The information from the molecular analysis of the GBS isolates is summarised in Table 2 . Fig. 1 . Study flow-chart. *Recruitment started during working hours, but because delivery was prolonged, these children were born at the weekend, when the laboratory was not available and some information was lost. 
DISCUSSION
This study presents the first comprehensive effort to determine the prevalence of GBS colonization, serotype distribution and associated risk factors for this infection during pregnancy in Morocco, a country for which no clear preventive measures have been implemented to decrease the burden and morbidity associated with vertical GBS transmission. The prevalence of GBS colonization in the pregnant women of the study was 24 %, a similar figure to those in previous smaller studies in other areas of the country that included pregnant women directly in the delivery room (20.5 % in Marrakech and 23.3 % in Fez) [14, 15] . Such carriage rates were also in line with those described in other countries of the North African/Middle Eastern region (22 %) and those in more recent data from Sub-Saharan Africa [16] [17] [18] [19] , but generally higher than the overall regional estimate of 18 % [18, 19] . Importantly, GBS was confirmed as an important cause of neonatal invasive A probability of <0.05 was considered statistically significant. Bold, statistically significant. *Vagino-rectal or vaginal samples from pregnant women for which strains were available for molecular analysis. †Peripheral samples of colonized newborns born of recruited mothers for which strains were available for molecular analysis. ‡Infants recruited at the neonatal intensive care unit with clinical sepsis and with at least one newborn body surface (NBS) sample that was positive for group B streptococcus and available for molecular analysis. §Infants recruited at the neonatal intensive care unit with clinical sepsis and blood culture that was positive for group B streptococcus. ||Fisher's exact test.
bacterial disease, as it was detected in 3 % (5/160) of the additional studied neonates with suspected neonatal sepsis.
In this study, GBS colonization was significantly associated with hypertension during the current pregnancy. This association has not been reported in similar studies conducted elsewhere [15, 16, [20] [21] [22] [23] . The association between pregnancy-related hypertension and asymptomatic bacteriuria has been noted in the past [24] . E. coli-associated gastrointestinal infections during pregnancy have also been linked with maternal hypertension, and infection and inflammation may be involved in the pathogenesis of preeclampsia [25] [26] [27] [28] . The mechanisms of this association and the true impact of such a finding need to be confirmed and further explored.
Our study also confirmed an association between GBS carriage and vaginal pruritus, an easily detectable clinical symptom. Classically, GBS colonization has been considered to be asymptomatic [29] . Co-infections could be the cause of the pruritus, acting as potentially confounding factors, but this seems unlikely because no association between GBS and E. coli co-infection or between the presence of vaginal E. coli and pruritus could be found. Similarly, the association even persisted in the group with a normal Nugent score, ruling out bacterial vaginosis as an alternative explanation. The true meaning of this finding, and its potential public health implications, also warrant further research.
No other reported risk factors for GBS colonization, such as race, smoking, age, diabetes, multiple partners, Candida colonization, intravaginal cleaning, anaemia and seasonality, among others, were identified in this study [16, 17, 20, [30] [31] [32] [33] [34] . This limitation can be explained in part by the low prevalence of some conditions in our study (e.g. differences in race) and the heterogeneity of the populations evaluated in other studies, which often included non-pregnant women, HIV-infected women or pregnant women at other gestational ages [16, 17, 20, [30] [31] [32] [33] [34] .
GBS colonization in newborns was significantly associated with colonization in their mothers (P<0.001). A positive maternal vaginal culture is the strongest risk factor for neonatal infection, which is in concordance with the results of this study [29] . It is, however, important to note that two colonized newborns were born of pregnant women with a negative vagino-rectal culture.
The GBS strains isolated in this Moroccan setting were fully susceptible to penicillin and ampicillin, which supports these two antibiotics remaining as the first-line treatment and prophylaxis option. However, the observed resistance to clindamycin (6 %) and erythromycin (9 %) could constitute a clinical problem in cases of allergy to penicillin, as these are the recommended alternatives [5] .
Importantly, the previously described association between maternal colonization with GBS and E. coli [16] was not observed in this study. This may be due to the lower prevalence of E. coli colonization, although a borderline association was observed between colonization of the pregnant woman by E. coli and GBS-positive cultures in the newborn, suggesting that a relationship between the two bacteria is plausible. This finding, if further confirmed, would have important public health implications, as treating GBS/E. coli co-infections with penicillin/ampicillin would appear to be inadequate, as up to 20 % of circulating E. coli isolates may be resistant to such antimicrobials [35] .
The geographical diversity of GBS serotype distribution has been reported over time [36] [37] [38] , with the capsular polysaccharide type III being the major culprit for GBS disease, causing more than 60 % of all global cases [39] . A pentavalent conjugate vaccine including serotypes Ia, Ib, II, III and V could thus prevent 85-98 % of the global GBS neonatal disease [1, 19] . In Rabat, the two most common serotypes were V and II, both clearly related to invasive infection [40] , closely followed by serotype III. In spite of the differences observed in this series, it is important to highlight the fact that such a vaccine, currently under development, would have been effective against almost 90 % of the colonizing cases found in this setting, with the other candidate trivalent vaccine only being able to prevent 28 % of the cases. In this study, serotype IV was observed in 6 % of the colonized pregnant women, which is similar to the data from other countries, such as Turkey, Brazil and the United States, and lower than in other Middle Eastern countries, such as the United Arab Emirates [41] [42] [43] [44] [45] . This might suggest that serotype IV is an emergent serotype, as it was significantly related to transmission and identified as a cause of invasive disease, suggesting that this non-vaccine serotype could play a role in neonatal sepsis in this area. It is important to highlight, however, that GBS vaccines have been designed to prevent invasive neonatal disease secondary to GBS, rather than to eradicate maternal GBS colonization. Therefore, it is the serotype distribution of invasive neonatal GBS disease that should guide the design of any future GBS vaccine. Our findings predominantly reflect the distribution of circulating serotypes carried by Moroccan mothers or their children, but not necessarily that of those responsible for invasive neonatal disease, as the numbers in this particular group were very small. Larger studies better characterizing septic infants with confirmed GBS disease in this setting are required to confirm the validity of the role of serotype IV and the potential repercussions of adding it to any new candidate GBS vaccine.
A limitation of this study is the absence of molecular characterization of the isolates with an analysis by multilocus sequence typing (MLST), which would significantly improve the results, as it would allow the comparison of the GBS genetic lineages circulating in Morocco with those in other countries. It would also be a valuable indicator for the analysis of vertical transmission when comparing the pregnant woman/neonate pairs.
Conclusion
In Rabat, GBS maternal colonization occurs in almost a quarter of pregnancies, and vertical transmission of this pathogen is therefore a real but preventable threat to offspring. Given the high prevalence of GBS colonization, the adequacy of the screening procedures, the absence of easily identifiable risk factors and the insufficiency of the current intrapartum risk factor policy, universal screening would be an acceptable option in Morocco. A cost-effectiveness and feasibility study should be conducted in order to evaluate whether universal screening for GBS during pregnancy is warranted, mirroring what is done in other parts of the world. Such a strategy could be a temporary solution in anticipation of the much-awaited pentavalent GBS maternal vaccine. 
